Your browser doesn't support javascript.
loading
C reactive protein utilisation, a biomarker for early COVID-19 treatment, improves lenzilumab efficacy: results from the randomised phase 3 'LIVE-AIR' trial.
Temesgen, Zelalem; Kelley, Colleen F; Cerasoli, Frank; Kilcoyne, Adrian; Chappell, Dale; Durrant, Cameron; Ahmed, Omar; Chappell, Gabrielle; Catterson, Victoria; Polk, Christopher; Badley, Andrew; Marconi, Vincent C.
Afiliación
  • Temesgen Z; Division of Infectious Diseases, Mayo Clinic, Rochester, Minnesota, USA temesgen.zelalem@mayo.edu.
  • Kelley CF; Division of Infectious Diseases, Emory University School of Medicine, Grady Memorial Hospital, Atlanta, Georgia, USA.
  • Cerasoli F; Medical Affairs, Rx Medical Dynamics, LLC, New York, New York, USA.
  • Kilcoyne A; Humanigen Inc, Burlingame, California, USA.
  • Chappell D; Humanigen Inc, Burlingame, California, USA.
  • Durrant C; Humanigen Inc, Burlingame, California, USA.
  • Ahmed O; Humanigen Inc, Burlingame, California, USA.
  • Chappell G; Humanigen Inc, Burlingame, California, USA.
  • Catterson V; BioSymetrics, Inc, New York, New York, USA.
  • Polk C; Infectious Disease, Atrium Health, Charlotte, North Carolina, USA.
  • Badley A; Division of Infectious Diseases, Mayo Clinic, Rochester, Minnesota, USA.
  • Marconi VC; Division of Infectious Disease, Emory University School of Medicine, Rollins School of Public Health, and Emory Vaccine Center, Atlanta, Georgia, USA.
Thorax ; 78(6): 606-616, 2023 06.
Article en En | MEDLINE | ID: mdl-35793833

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: COVID-19 Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Revista: Thorax Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: COVID-19 Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Revista: Thorax Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos